Otsuka and Bristol-Myers Squibb

Hunton House, Highbridge Estate, Oxford Road, Uxbridge, Middlesex, UB8 1DH, UK
Telephone: +44(0)1895 207100 (Otsuka)
Telephone: +44(0)1895 523000 (BMS)
Fax: +44 (0)1895 523010 (BMS)
Fax: +44(0)1895 523677 BMS
Fax: +44 (0)1895 207115 (Otsuka)
Medical Information Direct Line: +44(0)800 731 1736 BMS
Medical Information e-mail: medical.information@bms.com
Patient Information Leaflet last updated on the eMC: 09/06/2009
PIL Abilify 7.5 mg/ml solution for injection (intramuscular) (Otsuka & Bristol-Myers Squibb)

When a pharmaceutical company changes an SPC or PIL, a new version is published on the eMC. For each version, we show the dates it was published on the eMC and the reasons for change.

Updated on 09/06/2009 and displayed until Current
Reasons for adding or updating:
  • Improved Electronic Presentation
  • Change to date of revision
Updated on 24/06/2008 and displayed until 09/06/2009
Reasons for adding or updating:
  • Changes to therapeutic indications
  • Change to date of revision
  • Change to, or new, use for medicine
  • Change to side-effects
Updated on 25/04/2008 and displayed until 24/06/2008
Reasons for adding or updating:
  • New PIL for new product

Active Ingredients/Generics

 
   aripiprazole


© 2009 Datapharm Communications Ltd

Go to www.medicines.org.uk